---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-003510"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2026-07-16T20:07:03+00:00"
generated_at: "2026-07-16T20:08:08.981644+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Entera Bio shareholders approve 2.5x increase in authorized shares to 350M and 2.5M share increase in equity plan

## Summary
- Authorized ordinary shares increased from 140,010,000 to 350,000,000 effective July 14, 2026.
- 2018 Equity Incentive Plan amended to add 2,500,000 ordinary shares for issuance.
- All director nominees elected: Sean Ellis, Steven D. Rubin, Geno H. Germano (Class III, three-year terms).
- Shareholders approved non-executive director compensation, share-based grants, and advisory say-on-pay.
- Kesselman & Kesselman (PwC) ratified as independent auditor for FY 2026.

## SEC filing metadata
- accession: 0001178913-26-003510
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2026-07-16T20:07:03+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891326003510/0001178913-26-003510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891326003510/zk2635691.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-003510
- JSON: https://secwatch.observer/filing/0001178913-26-003510.json
- Plain text: https://secwatch.observer/filing/0001178913-26-003510.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.